Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThere is no licensed 60mg tirzepatide dose in the UK. The medicine sold here as Mounjaro comes in six strengths — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg — each delivering four weekly injections per pen. If you have seen "tirzepatide 60mg" mentioned online, it almost certainly refers to unlicensed peptide powders intended for research use, not regulated weight-loss treatment. Understanding why that distinction matters is worth your time before you make any decisions about treatment. Tirzepatide is a prescription-only medicine; a prescriber, not an algorithm, decides whether it is suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across three tirzepatide doses: 5mg, 10mg and 15mg weekly. At 15mg, participants lost an average of around 20–21% of body weight over 72 weeks. These figures represent the ceiling of what the clinical programme tested in a controlled, blinded trial. There was no 60mg 3ml tirzepatide arm, no 30mg arm, and the dose escalation was deliberately cautious, starting at 2.5mg to let the body adjust before stepping up in 4-week intervals.
NICE reviewed this evidence when it appraised tirzepatide in December 2024 (TA1026). The resulting recommendation covers adults with a BMI of 35 or above plus at least one weight-related condition, using the licensed dose schedule. Higher doses were not part of that appraisal because they were not part of the trial. The 15mg pen is where the evidence base ends, and that boundary exists for good reason.
You can read NICE's full appraisal of tirzepatide (TA1026) to see exactly which population the recommendation covers and what supporting evidence was considered.
Search for "tirzepatide 60mg" and you will find suppliers selling vials of peptide powder labelled at various concentrations, including 60mg. These products require reconstitution before use, dissolving the powder in bacteriostatic water and then drawing up doses with a syringe. They are sometimes described as being "for research purposes only".
This is a separate world from the pharmacy shelf. Mounjaro, which you can read more about on our Mounjaro overview page, is manufactured under pharmaceutical-grade conditions, filled into pre-set KwikPens, and batch-tested before it leaves the factory. A tirzepatide peptide product sold in powder form has no such guarantees. The MHRA has no visibility over its purity or sterility, and there is no way for a buyer to verify what concentration they are actually injecting. The agency has warned repeatedly about counterfeit and unverified weight-loss products circulating online; peptide powders fall squarely within that concern.
It is also worth noting that calculating a dose from a reconstituted powder requires accurate measurement to a fraction of a millilitre. Even a small error changes the effective dose meaningfully. The pre-filled KwikPen exists precisely to remove that variable.
The Mounjaro KwikPen sits in the fridge door between uses, straightforward to incorporate into most households, and clearly labelled with its exact dose. That predictability is built into the design. Reconstituted peptide solutions require similar refrigeration but introduce additional variables: how accurately the powder was weighed, what water was used, and how long the solution remains stable once mixed.
For licensed treatment, storage details and stability windows are set out in the official SmPC, which is published on the electronic Medicines Compendium (eMC). This is the document prescribers and pharmacists refer to. If you are ever uncertain about how to store your medication, that document and your prescriber are the right sources, not general advice online.
If you are curious about how licensed tirzepatide treatment works from a practical standpoint, our tirzepatide guide covers the full picture, or you can explore weight-loss treatment options more broadly.
The clinical case for tirzepatide is strong. The trial evidence that convinced NICE was built on licensed doses, a regulated supply chain and medical oversight throughout. None of that applies to unlicensed peptide powders, whatever the label says.
If you meet the eligibility criteria for licensed treatment (broadly, a BMI of 30 or above, or 27 or above with a relevant health condition) the licensed route is the one with evidence behind it. It is also worth understanding the cost context: private tirzepatide treatment pricing varies by dose and provider. Our Mounjaro pricing page explains what goes into a legitimate private prescription cost, which is a different question from what an unlicensed powder costs per gram.
A prescriber considers your full health picture before recommending any treatment, including which dose to start on and how to titrate safely. That process cannot be replicated by selecting a vial from a website. If you would like to understand whether licensed tirzepatide is right for you, speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.